Rituximab filed in US for common leukaemia
This article was originally published in Scrip
Executive Summary
Genentech (Roche) and Biogen Idec have filed two supplemental BLAs with US FDA for their blockbuster non-Hodgkin's lymphoma (NHL) drug Rituxan (rituximab) to treat both previously untreated and treated chronic lymphocytic leukaemia (CLL), the most common form of adult leukaemia.